What therapeutic effects can Alpelisib achieve and is its effect stable?

Apelix is a selective PI3Kα inhibitor, mainly used to treat patients with PIK3CA gene mutationsHRpositive/HER2negative advanced breast cancer. The drug, used in combination with fulvestrant, has been proven to significantly extend progression-free survival (PFS). In the SOLAR-1 clinical study, the median PFSPFSPFSof patients with PIK3CA mutations treated with apelvis combined with fulvestrant pan>It has reached 11 months, while fulvestrant alone is only 5.7 months. The efficacy has been significantly improved, and it is especially suitable for patients who have failed standard endocrine therapy.

In terms of therapeutic effect, Apelvis showed high objective response rate (ORR) and disease control rate (DCR). SOLAR-1 studies have shown that its combination with fulvestrant can achieve an objective response rate of more than 35% in patients with PIK3CA mutations, and more than 76% of patients can achieve disease control. This shows that apelvis has a relatively stable effect in delaying tumor progression and reducing tumor burden, and can even maintain a longer-term remission state for some patients.

Apelix targets a patient population that is often resistant to traditional endocrine therapy. Since PIK3CA mutations activate downstream signaling pathways, thus bypassing endocrine suppression, apelvis can effectively reverse the drug-resistant state and restore the sensitivity of tumors to hormone blockade by inhibiting this pathway. For patients who have been treated with AI drugs but have progressed, Apelvis provides a new treatment breakthrough, and its stable efficacy also makes it one of the important options for later-line treatment.

Although the efficacy of Apelvis is accurate, its side effects (such as hyperglycemia, rash, diarrhea, etc.) are relatively common, and some patients have to interrupt or reduce their treatment due to adverse reactions, thus affecting the sustainability of the efficacy. Therefore, in order to ensure the stable performance of the treatment effect, it is recommended that patients regularly monitor blood sugar and liver function during the use of Apelvis, and adjust the plan in a timely manner when necessary to achieve a balance between efficacy and safety. Overall, apelvis is a trustworthy targeted treatment option as long as side effects are managed appropriately.

Reference materials:https://www.drugs.com/